Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Janus Kinase Inhibitors Promising for Difficult-to-Treat RA

Michele B. Kaufman, PharmD, BCGP  |  July 27, 2021

EULAR 2021—Research shows Janus kinase inhibitors (jakinibs) may be a treatment option for patients with difficult-to-treat rheumatoid arthritis (RA) for whom at least two biologic disease-modifying antirheumatic drugs (bDMARDs) have proved ineffective.1 Mari Kamiya, MD, PhD, department of rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan, presented the data during the virtual EULAR 2021 Congress, June 2–5.

For 20–30% of RA patients, the first bDMARD they try—usually a tumor necrosis factor inhibitor (TNFi )—is ineffective. Of these patients, about 20% experience secondary ineffectiveness due to anti-drug antibodies within the first two years of treatment. For these patients with refractory RA, the next treatment choice is a non-TNFi bDMARD. However, these patients need more treatment options, such as jakinibs, which are targeted synthetic DMARDs (tsDMARDs). These agents have demonstrated similar efficacy to bDMARDs and are approved in the U.S. and E.U. to treat RA.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

EULAR’s definition of difficult-to-treat RA includes the following obligatory elements:

  1. At least two bDMARDs and/or tsDMARDs that have different mechanisms of action prove ineffective after conventional synthetic DMARDs (csDMARDs) have proved ineffective—unless csDMARDs were contraindicated for the patient;
  2. The presence of at least one of the following:
    1. Moderate disease activity;
    2. Signs and/or symptoms suggestive of active disease;
    3. The inability to taper glucocorticoid treatment;
    4. Rapid radiographic progression; or
    5. Quality-of-life reduction caused by RA symptoms; and
  3. The rheumatologist and/or patient perceive the signs and/or symptoms of RA being managed as problematic.2

This clinical trial was a real-world efficacy study of approved jakinibs in patients with difficult-to-treat RA. In December 2019, researchers retrospectively evaluated patients treated at their hospital for whom at least two bDMARDs proved inadequate and patients who had been switched to jakinibs. Drug retention rates were determined, and statistical tests were used to predict jakinib use for more than one year.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The following patient data were used at the time of jakinib initiation: age, gender, disease duration and number of bDMARDs used with or without methotrexate and/or glucocorticoids. Researchers also examined patient disease activity scores, erythrocyte sedimentation rates, the presence of rheumatoid factor/anti-CCP antibody, matrix metalloproteinase 3 value and Health Assessment Questionnaire Disability index.

Results

A total of 915 bDMARDs were administered to 394 patients with RA. The bDMARD retention rate and number of bDMARDs used at one year were 89.3% and 1.48 bDMARDs, respectively.

At one year, the retention rate for patients who took tofacitinib (n=65) was 60.2% and 67.2% for patients who took baricitinib (n=70). For patients with difficult-to-treat RA, the drug retention rates were 50.8% for tofacitinib (n=38) and 66.3% for baricitinib (n=35), with no significant difference. At five years, the bDMARD retention rate and number of bDMARDs used per patient were 67.7% and 2.27 bDMARDs, respectively. At 10 years, the bDMARD retention rate and number of bDMARDs used per patient were 52% and 3.15 bDMARDs, respectively.

Also at one year, no specific patient background factors predicting jakinib continuation were found. These results show that—although this was a small number of retrospectively evaluated patients—patients with difficult-to-treat RA may be effectively treated with the jakinibs baricitinib and tofacitinib, regardless of background demographics or disease parameters. The authors note that switching between jakinibs and the use of other jakinibs require further investigation.


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. Kamiya M, Togawa D, Mori S, et al. Efficacy of janus kinase inhibitors for difficult-to-treat RA in clinical practice [abstract POS0088]. Ann Rheum Dis. 2021 Jun;80(suppl 1):252–253.
  2. Nagy G,  Roodenrijs NMT, WEsing PMJ, et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2021 Jun;80(1):31–35.

Page: 1 2 | Multi-Page
Share: 

Filed under:Drug UpdatesMeeting ReportsRheumatoid Arthritis Tagged with:baricitinibEULARJAK inhibitorjakinibJanus Kinase InhibitorsRheumatoid Arthritis (RA)Tofacitinib

Related Articles

    Long-Term Benefits, Risks of Biologic Disease-Modifying Anti-Rheumatic Drugs in Patients with RA

    December 19, 2017

    Green Apple / shutterstock.com Two decades have passed since the first biologic disease-modifying anti-rheumatic drug (bDMARD) was approved. Studies on the long-term use of biologics in different disease states, such as for cardiovascular disease (CVD) and malignancy, as well as for knee/hip replacement, reveal some encouraging news. In clinical trials, bDMARDs have been shown to…

    Janus kinase 1 protein.

    Researchers Give Update on Janus Kinase (JAK) Inhibitors

    May 15, 2020

    The Janus kinase 1 protein. StudioMolekuul / shutterstock.com SNOWMASS VILLAGE, COLO.—Janus kinase inhibitors—or Jakinibs—are a relatively new class of disease-modifying anti-rheumatic drugs (DMARDs) that perform well and have a safety profile comparable to biologics. This group of drugs was the subject of The New Frontier: Comparative Safety of JAK Inhibitors, a presentation given at the…

    The Great Debate: Should Jakinibs Be Used Before Biologics after Methotrexate Failure in RA?

    November 9, 2020

    ACR CONVERGENCE 2020—In many ways, the current plethora of treatment options for rheumatoid arthritis patients represents an embarrassment of riches. However, while many therapeutics approved by the U.S. Food & Drug Administration (FDA) are available, knowing the order in which to try these medications with patients can be quite challenging. In The Great Debate, held…

    Research Outlines Benefits of bDMARDs to Treat Early RA

    February 10, 2021

    Sapart et al. suggest a combination of methotrexate and biologic disease-modifying anti-rheumatic drugs as induction therapy for patients with early RA may lead to long-term remission.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences